Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT04538664 (PAPILLON) für Nicht-kleinzelliges Lungenkarzinom ist aktiv, nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON) Phase 3 308
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT04538664 (PAPILLON) untersucht Behandlung im Zusammenhang mit Nicht-kleinzelliges Lungenkarzinom. Diese interventionsstudie der Phase 3 hat den Status aktiv, nicht rekrutierend und startete am 13. Oktober 2020. Es ist geplant, 308 Teilnehmer aufzunehmen. Durchgeführt von Janssen Research & Development, LLC wird der Abschluss für 2. August 2027 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 19. März 2026 aktualisiert.
Kurzbeschreibung
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
Offizieller Titel
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Erkrankungen
Nicht-kleinzelliges LungenkarzinomPublikationen
Wissenschaftliche Artikel und Forschungspapiere zu dieser klinischen Studie:Weitere Studien-IDs
- PAPILLON
- CR108850
- 61186372NSC3001 (Andere Kennung) (Janssen Research & Development, LLC)
- 2020-000633-40 (EudraCT-Nummer)
- 2023-506033-29-00 (Registerkennung) (EUCT number)
NCT-Nummer
Studienbeginn (tatsächlich)
2020-10-13
Zuletzt aktualisiert
2026-03-19
Studienende (vorauss.)
2027-08-02
Geplante Rekrutierung
308
Studientyp
Interventionsstudie
PHASE
Phase 3
Status
Aktiv, nicht rekrutierend
Stichwörter
EGFR Exon20ins Mutation
NSCLC
NSCLC
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellArm A: Amivantamab + Chemotherapy Participants will receive pemetrexed 500 milligram per meter square (mg/m\^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusi...Mehr anzeigen | Amivantamab Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase. Pemetrexed Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase. Carboplatin Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle. |
ExperimentellArm B: Chemotherapy Alone Participants will receive pemetrexed 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE ...Mehr anzeigen | Carboplatin Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle. Pemetrexed Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase. |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) | PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum). | From randomization to either disease progression or death whichever occurs first (up to 29 months) |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Objective Response Rate (ORR) | Up to 5 years 3 months | |
Duration of Response (DoR) | Up to 5 years 3 months | |
Overall Survival (OS) | Up to 5 years 3 months | |
Time to Subsequent Therapy (TST) | Up to 5 years 3 months | |
Progression-Free Survival After First Subsequent Therapy (PFS2) | Up to 5 years 3 months | |
Time to Symptomatic Progression (TTSP) | Up to 5 years 3 months | |
Number of Participants Treatment-emergent Adverse Events (TEAEs) | From Day 1 to 5 years 2 months | |
Number of Participants TEAEs With Severity | From Day 1 to 5 years 2 months | |
Number of Participants With Clinical Laboratory Abnormalities | Up to 5 years 3 months | |
Number of Participants With Vital Signs Abnormalities | Up to 5 years 3 months | |
Number of Participants With Physical Examination Abnormalities | Up to 5 years 3 months | |
Serum Concentration of Amivantamab | Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1) | |
Number of Participants With Anti-Amivantamab Antibodies | Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1) | |
Change From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) | From baseline to 5 years 3 months | |
Change From Baseline in Patient Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF) | From baseline to 5 years 3 months |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation
- Participant must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Participant must agree to genetic characterization of tumor status through the required pretreatment tumor biopsy (or submission of equivalent archival material), as well as baseline and periodic blood samples for analysis of tumor mutations in the bloodstream
- A female participant of childbearing potential must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
- Participant has evidence of synchronous NSCLC disease (as suggested by genetic characterization or radiographic appearance)
- Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and off corticosteroid treatment for at least 2 weeks prior to randomization is eligible)
- Participant has history of spinal cord compression that has not been treated definitively with surgery or radiation
- Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD, or radiation pneumonitis
- Participant has a contraindication to the use of carboplatin or pemetrexed (refer to local prescribing information for each agent). Participant has a history of hypersensitivity to, or cannot take, vitamin B12 or folic acid
Janssen Research & Development, LLCKeine Kontaktdaten vorhanden
229 Studienstandorte in 26 Ländern
Zentralklinik Bad Berka GmbH, Bad Berka, 99437, Germany
Evangelische Lungenklinik Berlin, Berlin, 13125, Germany
Universitaetsklinikum Koeln, Cologne, 50937, Germany
Kliniken der Stadt Koeln gGmbH, Cologne, 51109, Germany
Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting, Gauting, 82131, Germany
Thoraxklinik am Universitatsklinikum Heidelberg, Heidelberg, 69126, Germany
Onkologische Schwerpunktpraxis, Heilbronn, 74072, Germany
Bethanien Krankenhaus, Moers, 47441, Germany
Pius-Hospital Oldenburg, Oldenburg, 26121, Germany
Oncologianova GmbH, Recklinghausen, 45659, Germany
UZ Leuven, Leuven, 3000, Belgium
Algemeen Ziekenhuis Delta, Roeselare, 8800, Belgium
CHU UCL Namur - Site Godinne, Yvoir, 5530, Belgium
California
City of Hope 2, Duarte, California, 91010, United States
University of California Irvine, Orange, California, 92868, United States
UCLA, Santa Monica, California, 90404, United States
District of Columbia
Georgetown University Hospital, Washington D.C., District of Columbia, 20007, United States
Florida
H. Lee Moffitt Cancer & Research Institute, Tampa, Florida, 33612, United States
Georgia
University Cancer And Blood Center LLC, Athens, Georgia, 30607, United States
Michigan
Henry Ford Hospital, Detroit, Michigan, 48202, United States
Missouri
Washington University Medical Center, St Louis, Missouri, 63110, United States
New Jersey
Regional Cancer Care Associates LLC, East Brunswick, New Jersey, 08816, United States
New York
Langone Health at NYC University, NYU School of Medicine, New York, New York, 10016, United States
Columbia University Medical Center, New York, New York, 10032, United States
Oregon
Providence Portland Medical Center, Portland, Oregon, 97213, United States
South Dakota
Sanford Health, Sioux Falls, South Dakota, 57104, United States
Texas
Texas Oncology Pa, Tyler, Texas, 75702, United States
Utah
Utah Cancer Specialists, Salt Lake City, Utah, 84106, United States
Virginia
Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States
Blue Ridge Cancer Care, Salem, Virginia, 24153, United States
Chris O'Brien Lifehouse, Camperdown, 2050, Australia
St George Hospital, Kogarah, 2217, Australia
Cabrini Medical Centre, Malvern, 3144, Australia
Sir Charles Gairdner Hospital, Nedlands, 6009, Australia
Fundacao Pio XII, Barretos, 14784-400, Brazil
Cetus Oncologia, Belo Horizonte, 30110-017, Brazil
Ynova Pesquisa Clinica, Florianópolis, 88020-210, Brazil
Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda, Ijuí, 98700-000, Brazil
Liga Norte Riograndense Contra O Cancer, Natal, 59062 000, Brazil
UPCO Unidade de Pesquisa Clinica em Oncologia, Pelotas, 96020 080, Brazil
Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, 90020-090, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS, Porto Alegre, 90610-000, Brazil
Ministerio da Saude Instituto Nacional do Cancer, Rio de Janeiro, 20231 050, Brazil
Oncoclinicas Rio de Janeiro S A, Rio de Janeiro, 22 250 905, Brazil
Instituto D Or de Pesquisa e Ensino IDOR, Rio de Janeiro, 22281 100, Brazil
Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, São Paulo, 01246 000, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center, São Paulo, 01509 900, Brazil
Núcleo de Pesquisa São Camilo, São Paulo, 04014-002, Brazil
IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado, Sorocaba, 18030-075, Brazil
Hospital Evangélico de Cachoeiro de Itapemirim, Vitória, 29308-014, Brazil
Ontario
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada
Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada
Quebec
McGill University Health Centre, Montreal, Quebec, H4A 3J1, Canada
Beijing Cancer Hospital, Beijing, 100142, China
Chinese PLA General Hospital, Beijing, 100853, China
Beijing Chest hospital, Capital medical university, Beijing, 101199, China
Peking University International Hospital, Beijing, 102206, China
Jilin cancer hospital, Changchun, 130000, China
Hunan Cancer hospital, Changsha, 410013, China
The First People's Hospital Of Changzhou, Changzhou, 213003, China
West China Hospital Sichuan University, Chengdu, 610041, China
Chongqing University Cancer Hospital, Chongqing, 400030, China
Fujian Medical University Union Hospital, Fuzhou, 350001, China
The First Affiliated Hospital Sun Yat sen University, Guangzhou, 510080, China
The First Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, 310003, China
The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, 310009, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, 310016, China
Zhejiang Cancer Hospital, Hangzhou, 310022, China
Harbin medical university cancer hospital, Harbin, 150000, China
Taizhou Hospital of Zhejiang Province, Linhai, 317000, China
Nanjing Drum Tower Hospital, Nanjing, 210031, China
Shanghai Chest Hospital, Shanghai, 200030, China
Fudan University Shanghai Cancer Center, Shanghai, 200032, China
Shanghai East Hospital, Shanghai, 200123, China
Shanghai Pulmonary Hospital, Shanghai, 200433, China
Shengjing Hospital Of China Medical University, Shenyang, 110004, China
Cancer hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, 518116, China
Tianjin Medical University General Hospital, Tianjin, 300052, China
Weifang People's Hospital, Weifang, 261000, China
TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology, Wuhan, 430030, China
Hospital of Jiangnan University, Wuxi, 214122, China
The First Affiliated Hospital of Xian Jiaotong University, Xi'an, 710061, China
Yantai Yuhuangding Hospital, Yantai, 264000, China
Henan Cancer Hospital, Zhengzhou, 450008, China
Institut Bergonie, Bordeaux, 33000, France
Hospices Civils de Lyon HCL, Bron, 69500, France
Centre Georges Francois Leclerc, Dijon, 21000, France
Centre Hospitalier Le Mans, Le Mans, 72037, France
CHR Hôpital Calmette, Lille, 59037, France
CHU Nantes - Hopital Nord Laënnec, Nantes, 44093, France
Institut Curie, Paris, 75005, France
CHU Bordeaux, Pessac, 33604, France
HIA Begin, Saint-Mandé, 94163, France
Orszagos Koranyi Tbc es Pulmonologiai Intezet, Budapest, H-1529, Hungary
Mátrai Gyógyintézet-Bronchológia, Gyöngyös, 3233, Hungary
Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz, Székesfehérvár, 8000, Hungary
Markusovszky Egyetemi Oktatokorhaz, Szombathely, 9700, Hungary
Tudogyogyintezet Torokbalint, Törökbálint, 2045, Hungary
Basavatarakam Indo-American Hospital, Hyderabad, 500034, India
Tata Medical Center, Kolkata, 700160, India
Tata Memorial Hospital, Mumbai, 400012, India
HCG Manavta Cancer Centre, Nashik, 422002, India
Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, 110085, India
Noble Hospital Pvt Ltd, Pune, 411013, India
Shaare Zedek Medical Center, Jerusalem, 91031, Israel
Hadassah Medical Center, Jerusalem, 9112001, Israel
Meir Medical Center, Kfar Saba, 44281, Israel
Rabin Medical Center, Petah Tikva, 49100, Israel
Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel
A O U Sant Orsola Malpighi, Bologna, 40138, Italy
Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico, Catania, 95123, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, 47014, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy
IRCCS Ospedale San Raffaele, Milan, 20132, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy
San Gerardo Hospital, Monza, 20052, Italy
Ospedale S. Maria Delle Croci, Ravenna, 48121, Italy
Irccs Gemelli, Roma, 00168, Italy
Istituto Clinico Humanitas, Rozzano, 20089, Italy
Juntendo University Hospital, Bunkyō City, 113 8431, Japan
Saitama Medical University International Medical Center, Hidaka, 350-1298, Japan
National Hospital Organization Himeji Medical Center, Himeji, 670-8520, Japan
Kansai Medical University Hospital, Hirakata, 573 1191, Japan
Kanazawa University Hospital, Kanazawa, 920 8641, Japan
National Cancer Center Hospital East, Kashiwa, 277 8577, Japan
Kishiwada City Hospital, Kishiwada, 596-8501, Japan
Kobe City Medical Center General Hospital, Kobe, 650-0047, Japan
Kurashiki Central Hospital, Kurashiki, 710-8602, Japan
Kurume University Hospital, Kurume, 830-0011, Japan
Matsusaka Municipal Hospital, Matsusaka, 515-8544, Japan
National Hospital Organization Nagoya Medical Center, Nagoya, 460-0001, Japan
Aichi Cancer Center Hospital, Nagoya, 464 8681, Japan
Niigata Cancer Center Hospital, Niigata, 951-8566, Japan
Kindai University Hospital, Osaka Sayama Shi, 589 8511, Japan
Kitasato University Hospital, Sagamihara, 252-0375, Japan
Hokkaido University Hospital, Sapporo, 060-8648, Japan
Iwate Medical University Hospital, Shiwa-gun, 028-3695, Japan
Shizuoka Cancer Center, Shizuoka, 411 8777, Japan
The Cancer Institute Hospital of JFCR, Tokyo, 135 8550, Japan
Ehime University Hospital, Toon-shi, 791-0295, Japan
Wakayama Medical University Hospital, Wakayama, 641 8510, Japan
National Hospital Organization Yamaguchi Ube Medical Center, Yamaguchi, 755-0241, Japan
Hospital Pulau Pinang, George Town, 10990, Malaysia
Hospital Sultan Ismail, Johor Bahru, 81100, Malaysia
Hospital Kuala Lumpur, Kuala Lumpur, 50586, Malaysia
University Malaya Medical Centre, Kuala Lumpur, 59100, Malaysia
Centro Oncologico de Chihuahua, Chihuahua City, 31217, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, 44280, Mexico
Mexico Centre for Clinical Research, S.A. de C.V., Mexico City, 03100, Mexico
Médica Sur, Mexico City, 14050, Mexico
Instituto Nacional de Cancerologia, Mexico City, 14080, Mexico
Health Pharma Professional Research, México, 03100, Mexico
i Can Oncology Center, Monterrey, 64710, Mexico
Oncologia Integral Satelite, Naucalpan, 53100, Mexico
Centrum Onkologii im Prof F Lukaszczyka, Bydgoszcz, 85 796, Poland
Uniwersyteckie Centrum Kliniczne, Gdansk, 80 214, Poland
Szpitale Pomorskie Sp z o o, Gdynia, 81 519, Poland
Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie, Olsztyn, 10-357, Poland
Private Specialist Hospitals - MedPolonia, Poznan, 60-693, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw, 02-781, Poland
Hosp. Cuf Descobertas, Lisbon, 1998-018, Portugal
Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos, Lisbon, G1R 2J6, Portugal
Centro Hospitalar Universitario do Porto, EPE, Porto, 4099-001, Portugal
Instituto Portugues de Oncologia, Porto, 4200-072, Portugal
Centro Hospitalar de Vila Nova de Gaia Espinho E P E, Vila Nova de Gaia, 4434 502, Portugal
Pan American Center for Oncology Trials LLC, Rio Piedras, 00935, Puerto Rico
Irkutsk Regional Oncology Dispensary, Irkutsk, 664035, Russia
Moscow City Oncology Hospital № 62, Krasnogorsk, 143423, Russia
Krasnoyarsk Regional Oncology Dispensary, Krasnoyarsk, 660133, Russia
Leningrad Regional Oncology Dispensary, Kuzmolovsky, 188663, Russia
MCK, Moscow, 115533, Russia
City Clinical Hospital #1, Nal'chik, 360000, Russia
Nizhny Novgorod Regional Oncological Dispensary, Nizhny Novgorod, 603000, Russia
Leningrad Regional Clinical Hospital, Saint Petersburg, 194291, Russia
Oncology Medical Clinics AV Medical group, Saint Petersburg, 196006, Russia
N.N. Petrov Research Institute Of Oncology, Saint Petersburg, 197758, Russia
Tomsk Cancer Research Institute, Tomsk, 634050, Russia
Bashkir State Medical University, Ufa, 450083, Russia
Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, 150054, Russia
Inje University Haeundae Paik Hospital, Busan, 48108, South Korea
National Cancer Center, Gyeonggi-do, 10408, South Korea
GyeongSang National University Hospital, Gyeongsangnam-do, 52727, South Korea
Chonnam National University Hwasun Hospital, Jeollanam-do, 58128, South Korea
Seoul National University Bundang Hospital, Seongnam-si, 13620, South Korea
Korea University Anam Hospital, Seoul, 02841, South Korea
Kangbuk Samsung Hospital, Seoul, 03181, South Korea
Severance Hospital Yonsei University Health System, Seoul, 03722, South Korea
Asan Medical Center, Seoul, 05505, South Korea
Samsung Medical Center, Seoul, 06351, South Korea
The Catholic University of Korea Seoul St Mary s Hospital, Seoul, 06591, South Korea
Hosp Univ A Coruna, A Coruña, 15006, Spain
Inst. Cat. D'Oncologia-Badalona, Badalona, 08916, Spain
Hosp. de La Santa Creu I Sant Pau, Barcelona, 08025, Spain
Hosp. Univ. Quiron Dexeus, Barcelona, 08028, Spain
Hosp Univ Vall D Hebron, Barcelona, 08035, Spain
Hosp. Univ. de Burgos, Burgos, 09003, Spain
Hosp. Gral. Univ. Gregorio Maranon, Madrid, 28007, Spain
Hosp. Univ. Ramon Y Cajal, Madrid, 28034, Spain
Hosp. Univ. 12 de Octubre, Madrid, 28041, Spain
Hosp. Univ. La Paz, Madrid, 28046, Spain
Hosp. Univ. Pta. de Hierro Majadahonda, Majadahonda, 28222, Spain
Hosp Virgen de La Victoria, Málaga, 29010, Spain
Clinica Univ. de Navarra, Pamplona, 31008, Spain
Hosp. Virgen Del Rocio, Seville, 41013, Spain
Hosp. Clinico Univ. Lozano Blesa, Zaragoza, 50009, Spain
Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung City, 807, Taiwan
Chang Gung Medical Foundation, Kaohsiung City, 833, Taiwan
Taipei Medical University Shuang Ho Hospital, New Taipei City, 23561, Taiwan
Chung Shan Medical University Hospital, Taichung, 402, Taiwan
China Medical University Hospital, Taichung, 40447, Taiwan
National Taiwan University Hospital, Taipei, 10002, Taiwan
Phramongkutklao Hospital and Medical College, Bangkok, 10400, Thailand
Siriraj Hospital, Bangkok, 10700, Thailand
Songklanagarind Hospital, Prince of Songkla University, Songkhla, 90110, Thailand
Adana City Hospital, Adana, 01060, Turkey (Türkiye)
Başkent University Medical Faculty Adana Application and Research Center, Adana, 01250, Turkey (Türkiye)
Gazi University Hospital, Ankara, 6560, Turkey (Türkiye)
Ankara Bilkent City Hospital, Ankara, 6800, Turkey (Türkiye)
Trakya University Medical Faculty, Edirne, 22030, Turkey (Türkiye)
Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd, Istanbul, 34098, Turkey (Türkiye)
Medipol Mega University Hospital, Istanbul, 34214, Turkey (Türkiye)
Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Istanbul, 34722, Turkey (Türkiye)
Izmir Medical Park Hospital, Izmir, 35580, Turkey (Türkiye)
Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4, Dnipro, 49102, Ukraine
Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies', Kyiv, 02091, Ukraine
National Cancer Institute, Kyiv, 03022, Ukraine
Edinburgh Cancer Centre Western General, Edinburgh, EH4 2XU, United Kingdom
The Royal Marsden NHS Trust, London, SW3 6JJ, United Kingdom
The Royal Marsden NHS Trust, Sutton, SM2 5PT, United Kingdom